ERYTHROMYCIN A DIHYDRATE
- Product Name
- ERYTHROMYCIN A DIHYDRATE
- CAS No.
- 59319-72-1
- Chemical Name
- ERYTHROMYCIN A DIHYDRATE
- Synonyms
- Erythromycin A, EvoPure;Roxithromycin Impurity A;ERYTHROMYCIN A, DIHYDRATE VETRANAL;Erythromycin A dihydrateQ: What is Erythromycin A dihydrate Q: What is the CAS Number of Erythromycin A dihydrate Q: What is the storage condition of Erythromycin A dihydrate
- CBNumber
- CB4502522
- Molecular Formula
- C37H67NO13.H2O
- Formula Weight
- 751.945
- MOL File
- 59319-72-1.mol
ERYTHROMYCIN A DIHYDRATE Property
- Melting point:
- 197.6 °C
Safety
- WGK Germany
- 2
- RTECS
- KF4375000
ERYTHROMYCIN A DIHYDRATE Chemical Properties,Usage,Production
Biological Activity
Erythromycin dihyrate is a macrolide antibiotic produced by actinomycetes with broad antibacterial activity. It acts by binding to the bacterial 50S ribosomal subunit and inhibits RNA-dependent protein synthesis by blocking transpeptidation and/or translocation reactions without affecting nucleic acid synthesis .
in vitro
Erythromycin dihyrate inhibits growth of P. falciparum with IC 50 and IC 90 values of 58.2 μM and 104.0 μM, respectively .
in vivo
Mice of the ddY strain began to receive Erythromycin dihyrate 7 days after inoculation of EAC cells, and CDF mice begins to receive Erythromycin dihyrate immediately after inoculation of P388 cells. Erythromycin dihyrate (gastric intubation; 0.1-50 mg/ kg; 30-120 days) decreases tumor growth from the dose of 5 mg/kg, mice receiving 1-10 mg/kg of Erythromycin dihyrate survives much longer than control mice, Only 10% of mice treated with 5 mg/kg of Erythromycin dihyrate had no evidence of tumor formation on day 60, and the mice are alive even at 120 days after inoculation. However, treatment with 50 mg/kg of Erythromycin dihyrate shortens mean survival time in tumorbearing mice by 4-5 days when it compares to controls.
| Animal Model: | Female ddY mice at the age of 6 weeks with EAC cells or CDF mice at the age of 6 weeks with P388 ce lls |
| Dosage: | 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg |
| Administration: | Gastric intubation; 30-120 days |
| Result: | Decrease tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortens the MST in tumorbearing mice. |